

# Microvascular Abnormality in Schizophrenia as Shown by Retinal Imaging

Madeline H. Meier, Ph.D.

Idan Shalev, Ph.D.

Terrie E. Moffitt, Ph.D.

Shitij Kapur, M.D., Ph.D.

Richard S.E. Keefe, Ph.D.

Tien Y. Wong, M.D., Ph.D.

Daniel W. Belsky, Ph.D.

HonaLee Harrington, B.S.

Sean Hogan, M.S.W.

Renate Houts, Ph.D.

Avshalom Caspi, Ph.D.

Richie Poulton, Ph.D.

**Objective:** Retinal and cerebral microvessels are structurally and functionally homologous, but unlike cerebral microvessels, retinal microvessels can be non-invasively measured in vivo by retinal imaging. The authors tested the hypothesis that individuals with schizophrenia exhibit microvascular abnormality and evaluated the utility of retinal imaging as a tool for schizophrenia research.

**Method:** Participants were members of the Dunedin Study, a population-representative cohort followed from birth with 95% retention. Study members underwent retinal imaging at age 38. The authors assessed retinal arteriolar and venular caliber for all members of the cohort, including individuals who developed schizophrenia.

**Results:** Study members who developed schizophrenia were distinguished by wider retinal venules, suggesting microvascular

abnormality reflective of insufficient brain oxygen supply. Analyses that controlled for confounding health conditions suggested that wider retinal venules are not simply an artifact of co-occurring health problems in schizophrenia patients. Wider venules were also associated with a dimensional measure of adult psychosis symptoms and with psychosis symptoms reported in childhood.

**Conclusions:** The findings provide initial support for the hypothesis that individuals with schizophrenia show microvascular abnormality. Moreover, the results suggest that the same vascular mechanisms underlie subthreshold symptoms and clinical disorder and that these associations may begin early in life. These findings highlight the promise of retinal imaging as a tool for understanding the pathogenesis of schizophrenia.

(*Am J Psychiatry* 2013; 170:1451–1459)

Retinal imaging is a simple, noninvasive technology for assessing microvascular abnormalities in living individuals diagnosed with schizophrenia. Cerebrovascular abnormalities have been discussed as a pathological feature in schizophrenia, beginning with Meynert (1) (see Figure S1 in the data supplement that accompanies the online edition of this article). Advances in fundus photography (photographing the interior surface of the eye) and retinal image analysis now allow for the accurate quantitative assessment of the condition of small retinal blood vessels in large population-based samples (2). Retinal microvessels can be used to gauge the condition of the cerebral microvessels, because retinal and cerebral blood vessels share similar embryological origins and are homologous in structure and function (3). Of particular interest is the caliber of the retinal arterioles and venules (i.e., the size of the internal space of these microvessels), as they are the most commonly studied retinal parameters in relation to cerebrovascular disease and, unlike other retinal parameters, they are dimensionally distributed in

the general population. Previous research has shown that narrower arterioles are linked to hypertension (4, 5), while wider venules predict risk of stroke, dementia, and other cerebrovascular diseases (2, 5–11). Wider venules are thought to reflect cumulative structural damage to the microvasculature and may indicate problems with the oxygen supply to the brain (2, 12). Thus, retinal venular caliber is a promising target for the first investigation of microvascular abnormality in living individuals diagnosed with schizophrenia. In this study, we tested the hypothesis that individuals with schizophrenia are distinguished by wider retinal venules, and we evaluated the utility of retinal imaging as a tool for schizophrenia research.

## Method

### Participants

Participants were members of the Dunedin Multidisciplinary Health and Development Study, a longitudinal investigation of the health and behavior of a complete birth cohort of consecutive

This article is featured in this month's *AJP Audio*, is the subject of a *CME* course (p. 1509), and is discussed in an *Editorial* by Dr. Malaspina (p. 1382)

births from April 1, 1972, to March 31, 1973, in Dunedin, New Zealand. The cohort of 1,037 children (91% of eligible births; 52% boys) was constituted at age 3 years. Cohort families represent the full range of socioeconomic status in the general population of New Zealand's South Island and are primarily white. Follow-up assessments were conducted at ages 5, 7, 9, 11, 13, 15, 18, 21, 26, 32, and, most recently, 38 years, when 95% of the 1,007 living study members underwent assessment in the period 2010–2012.

The study protocol was approved by the institutional ethical review boards of the participating universities, and study members gave informed consent before participating.

### Schizophrenia

Schizophrenia was assessed at ages 21, 26, 32, and 38. We previously described the schizophrenia cases up to age 32 (13–15), and here we update this information with data from age 38. Schizophrenia was assessed at each age with the Diagnostic Interview Schedule (DIS) (16, 17), using DSM criteria. To enhance the validity of our research diagnosis, we implemented special steps. First, we required the presence of hallucinations (not substance use-related) in addition to at least two other positive symptoms. This requirement is stricter than that of DSM-IV, which does not require hallucinations, although requiring them has been shown to reduce overdiagnosis (18). Second, because self-reports can be compromised by poor insight in schizophrenia, we required objective evidence of impairment resulting from psychosis, as reported by informants and as recorded in the study's life-history calendars, which document continuous histories of employment and relationships. Third, in our research, the DIS is administered by experienced clinicians, not lay interviewers. These clinicians record detailed case notes. Staff also rate observable symptoms manifested in affect, grooming, and speech during the full day that participants spend at our research unit. Fourth, participants bring their medications, which are then classified by a pharmacist. Fifth, informants report study members' positive and negative psychotic symptoms via postal questionnaires. Finally, study members' parents were interviewed about their adult child's psychotic symptoms and treatment as part of the Dunedin Family Health History Study (2003–2005). These data, accumulated in the Dunedin study at ages 21, 26, 32, and 38, were compiled into dossiers reviewed by four clinicians to achieve best-estimate diagnoses with 100% consensus. By age 38, 2% of the cohort (N=20) met criteria for schizophrenia and had, according to the multisource information collected in the dossiers, been hospitalized for schizophrenia (totaling 1,396 days of psychiatric hospitalization, according to official New Zealand administrative record searches) or received prescriptions for antipsychotic medications. An additional 1.7% (N=17) met all criteria, had hallucinations, and suffered significant life impairment but had not, to our knowledge, been treated specifically for psychotic illness. Together, these two groups constituted a total of 37 cases of diagnosed schizophrenia in the cohort. Of these 37 individuals, four died before the age-38 retinal vasculature assessment and two declined to participate. An additional four were excluded from the analysis because of pregnancy, a congenital health condition, or ungradable retinal images, leaving an effective group size of 27 (55% men) for this study.

The cohort's 3.7% prevalence rate of schizophrenia is high and should be understood in the context of three methodological aspects of our study. First, our birth cohort, with a 95% participation rate, allows us to count psychotic individuals overlooked by previous surveys because individuals with psychotic disorders often decline to participate in surveys or die prematurely (19), and surveys often exclude homeless or institutionalized individuals with psychosis. Second, our cohort members are all from one city in the South Island of New Zealand. It is possible, given

geographical variation in rates of schizophrenia (20–22), that the prevalence is somewhat elevated there. No data exist to compare prevalence rates of schizophrenia in New Zealand to rates in other countries, but the high prevalence of suicide in New Zealand could be consistent with an elevated prevalence of severe mental health conditions (23). Third, our research diagnoses did not make fine-grained distinctions among psychotic disorders (e.g., schizophrenia versus schizoaffective disorder). Thus, the cohort members diagnosed with schizophrenia here might not be considered by all clinicians to have schizophrenia. We note, however, that over half of those we diagnosed were confirmed by receipt of treatment. Moreover, etiological mechanisms appear to be similar across the continuum of psychosis (24).

### Comparison Groups

Study members who did not meet criteria for schizophrenia were classified into the comparison groups detailed below. We selected these medical and psychiatric comparison groups because 1) these conditions occur more commonly in individuals diagnosed with schizophrenia than in the general population, in this cohort and in other research (25, 26), and 2) hypertension, diabetes, and smoking have been associated with vessel caliber in previous retinal imaging studies (2, 5).

**Hypertension at age 38 (N=110).** Hypertension (27) was defined as a systolic blood pressure  $\geq 140$  mmHg or a diastolic blood pressure  $\geq 90$  mmHg (28). The prevalence of hypertension was 19% in the schizophrenia group and 12% in the rest of the cohort.

**Prediabetes/diabetes at age 38 (N=154).** Prediabetes and diabetes were defined according to the American Diabetes Association: a hemoglobin A<sub>1c</sub> level in the range of 5.7%–6.5% for prediabetes, and  $\geq 6.5\%$  for diabetes (29). The prevalence was 29% in the schizophrenia group and 18% in the rest of the cohort.

**Persistent tobacco dependence (N=210).** Cohort members who were diagnosed with DSM tobacco dependence on two or more occasions between ages 18 and 38 were classified into the persistent tobacco dependence group. The prevalence was 56% in the schizophrenia group and 23% in the rest of the cohort.

**Persistent depression (N=188).** Cohort members who were diagnosed with DSM depression on two or more occasions between ages 18 and 38 were classified into the persistent depression group. The prevalence was 70% in the schizophrenia group and 21% in the rest of the cohort.

**Healthy comparison subjects (N=412).** Healthy comparison subjects did not have any of the aforementioned health problems.

### Psychosis Symptoms

Childhood psychosis symptoms were assessed at age 11 for 789 cohort members seen at the Dunedin Unit (those assessed at school were not seen by the child psychiatrist) using the Diagnostic Interview Schedule for Children (30). As previously described (13), children responded to four questions (see Table S1 in the online data supplement). Responses were summed, and children with scores of 0, 1, and  $\geq 2$  were grouped as having no, weak, or strong symptoms, respectively.

Adulthood psychosis symptoms were assessed with the DIS at ages 21, 26, 32, and 38. Cohort members reported on eight symptoms of hallucinations and delusions (see Table S1 in the data supplement), which were summed into a single scale at each age. These four scales were used in a confirmatory factor analysis to estimate a continuous latent variable representing dimensional liability to adult psychosis across ages 21–38. Because the four scales had positive skew, they were treated as

ordinal, with values ranging from 0 to 8. Standardized factor loadings for the psychosis symptom scales at ages 21, 26, 32, and 38 were 0.60, 0.87, 0.81, and 0.83, respectively. The model fit for this single latent variable was excellent ( $\chi^2=2.13$ ,  $p=0.345$ ; root mean square error of approximation: 0.008, 95% CI=0.000–0.065; comparative fit index=1.00; Tucker-Lewis index=1.00).

### Assessment of Retinal Vessel Caliber

As previously described (31), digital fundus photographs were taken at the Research Unit after 5 minutes of dark adaptation. The same camera (a Canon NMR-45 with a 20D SLR backing) was used for all photographs. For each participating cohort member, both eyes were photographed, and measurements for the two eyes were averaged. Retinal photographs were graded at the Singapore Eye Research Institute, National University of Singapore, using semiautomated computer software (Singapore "I" Vessel Assessment [SIVA], version 3.0). Trained graders, blind to participant characteristics, used the SIVA program to measure the retinal vessel diameters according to a standardized protocol with high intergrader reliability (32). Caliber (or diameter) denotes the size of the lumen, which is the internal space of the vessel. Measurements were made for arterioles and venules where they passed through a region located 0.50–2.00 disk diameters from the optic disk margin (Figure 1) (32). Vessel calibers were based on the six largest arterioles and venules passing through this region and were summarized as central retinal artery equivalent and central retinal vein equivalent using the revised Knudtson-Parr-Hubbard formula (32, 33). Of 938 study members for whom retinal images were available, only seven could not be graded because the images were either too dark or not centered on the optic disk. An additional nine study members were excluded from analyses because of pregnancy. This left 922 study members for whom retinal vessel data were available. Arteriolar and venular calibers were normally distributed within the cohort. The mean arteriolar caliber among the 922 study members was 137.33 measuring units ( $SD=10.86$ , median=137.30, range=105.66–179.47), and the mean venular caliber was 196.20 measuring units ( $SD=14.83$ , median=195.51, range=141.07–245.68).


### Statistical Analysis

Before all analyses, arteriolar and venular caliber were each adjusted for the effect of the other vessel, as recommended (2, 34), in order to isolate the unique effects for each vessel and adjust for any potential effects of refractive errors (35). Vessel calibers were then standardized on the population-representative cohort (mean=0.00,  $SD=1.00$ ). Sex was included as a covariate in all analyses.

Our analyses proceeded as follows. First, to replicate previous studies documenting associations between vessel caliber and hypertension, diabetes, and smoking, we used analysis of variance to compare mean vessel calibers in each group with those in a group of healthy individuals (i.e., a group with none of the aforementioned conditions). Next, to test our hypothesis that individuals with schizophrenia are distinguished specifically by wider venules, we compared venular and arteriolar calibers in individuals with schizophrenia with those in individuals with hypertension, prediabetes/diabetes, persistent tobacco dependence, or persistent depression. As an additional check to ensure that an association between schizophrenia and wider venules could not be explained by the collective effects of these conditions, we conducted a multivariate regression, predicting venular caliber from schizophrenia while controlling for all of these conditions simultaneously. In this multivariate regression, we treated blood pressure (systolic and diastolic) and prediabetes/diabetes (i.e., hemoglobin A<sub>1c</sub> level) as continuous variables.

Second, to test our hypothesis that wider venular caliber is associated with psychosis symptoms in adulthood, we obtained

FIGURE 1. Retinal Digital Photograph<sup>a</sup>



<sup>a</sup> Measurements were made for the six largest arterioles (red) and venules (blue) passing through the region located 0.50–2.00 disk diameters from the optic disk margin.

the parametric correlation between latent dimensional liability to adult psychosis and venular caliber.

Third, to test our hypothesis that wider venular caliber is associated with psychosis symptoms in childhood, we obtained the polychoric correlation between childhood psychosis symptoms (a three-level ordinal variable), and venular caliber.

## Results

### Retinal Venular Caliber and Schizophrenia

Table 1 lists standardized mean venular and arteriolar calibers at age 38 for cohort members who developed schizophrenia ( $N=27$ ) and for each of the comparison groups. Mean values reflect effect sizes for how different each group is from the cohort norm. Differences between pairs of groups can also be interpreted as effect sizes. Effect sizes of 0.20, 0.50, and 0.80 reflect small, medium, and large effects, respectively (36).

The mean values indicate four noteworthy findings. First, as previous retinal imaging studies have found (2, 5), study members with hypertension, prediabetes/diabetes, and tobacco dependence all had wider venules than healthy study members. Second, study members diagnosed with schizophrenia had much wider venules at age 38 than all other groups except individuals with hypertension. Third, individuals with schizophrenia had wider venules than a psychiatric comparison group with persistent depression. Fourth, unlike the schizophrenia group, the hypertension group also had much narrower arterioles than all other groups. This is consistent with previous research linking narrower arterioles specifically to

TABLE 1. Standardized Mean Retinal Vessel Caliber for the Schizophrenia and Comparison Groups<sup>a</sup>

Group	N	Venule			Arteriole		
		Mean	SD	95% CI	Mean	SD	95% CI
Schizophrenia	27	0.59 <sup>b</sup>	1.16	0.14, 1.05	-0.13	1.04	-0.54, 0.28
Healthy	412	-0.20 <sup>c</sup>	0.91	-0.29, -0.12	0.15	0.93	0.06, 0.24
Hypertension	110	0.45 <sup>b</sup>	1.00	0.26, 0.64	-0.75 <sup>b,c</sup>	1.06	-0.95, -0.55
Prediabetes/diabetes	154	0.14 <sup>b,c</sup>	0.94	-0.01, 0.29	-0.08 <sup>b</sup>	1.00	-0.24, 0.08
Persistent tobacco dependence	210	0.17 <sup>b</sup>	1.10	0.02, 0.32	0.02	1.04	-0.12, 0.16
Persistent depression	188	0.13 <sup>b,c</sup>	1.11	-0.03, 0.29	-0.08 <sup>b</sup>	0.99	-0.22, 0.06

<sup>a</sup> Mean values for each vessel were adjusted for the other vessel and sex and were standardized on the population-representative cohort (mean=0.00, SD=1.00). Thus, means reflect effect sizes for how different each group is from the cohort norm. Differences between pairs of groups can also be interpreted as effect sizes. Effect sizes of 0.20, 0.50, and 0.80 reflect small, medium, and large effects, respectively.

<sup>b</sup> Significantly different from the healthy group.

<sup>c</sup> Significantly different from the schizophrenia group.

hypertension (2, 5) and suggests that hypertension cannot explain the wider venules in the schizophrenia group.

Schizophrenia was also associated with wider venular caliber in a multiple regression model, adjusted for arteriolar caliber and sex ( $\beta=0.61$ ,  $SE=0.19$ ;  $t=3.14$ ,  $df=920$ ,  $p=0.002$ ), and this association remained statistically significant after we also controlled for systolic blood pressure, diastolic blood pressure, hemoglobin A<sub>1c</sub> level, persistent tobacco dependence, and persistent depression ( $\beta=0.49$ ,  $SE=0.19$ ;  $t=2.57$ ,  $df=915$ ,  $p=0.011$ ). Wider venules among individuals diagnosed with schizophrenia could also not be explained by current use of antipsychotic medication; venular caliber for the subset of individuals diagnosed with schizophrenia who did not take antipsychotic medication during the year before retinal imaging ( $N=22$ ) was even wider (mean=0.69,  $SD=1.15$ ). Results were similar for those who had never ( $N=12$ , mean=0.63,  $SD=1.19$ ) compared with those who had ever ( $N=15$ , mean=0.56,  $SD=1.17$ ) received treatment specifically for psychotic illness.

Figure 2 shows the distribution of venular caliber (adjusted for arteriolar caliber and sex and standardized on the cohort) for each group. The figure shows that the distribution for venular caliber in the schizophrenia group was shifted to the right, reflecting wider venules. For example, 70% of the schizophrenia group members had venular calibers wider than the cohort mean ( $Z=0.00$ ), compared with only 40% of the healthy group ( $\chi^2=9.91$ ,  $p=0.002$ ). This nonparametric test does not depend on extreme outlier observations. Thus, a significantly larger proportion of individuals with schizophrenia had wider-than-average venules (regardless of outliers).

#### Retinal Venular Caliber and Liability to Adult Psychosis

Approximately one-third of the cohort endorsed one or more psychotic symptoms in adulthood, which were aggregated into a latent liability score. The association between this latent liability to adult psychosis and venular caliber, adjusted for arteriolar caliber and sex, was 0.15 ( $p<0.001$ ).

#### Retinal Venular Caliber and Childhood Psychosis Symptoms


Of the 13 cohort members who had significant psychotic symptoms at age 11, three were diagnosed with adult schizophrenia. The association between these childhood psychosis symptoms (age 11) and venular caliber (age 38), adjusted for arteriolar caliber and sex, was 0.13 ( $p=0.015$ ) (Figure 3).

## Discussion

In our population-based birth cohort, study members who developed schizophrenia exhibited retinal microvascular abnormality—specifically, wider venular caliber. Our analyses that controlled for confounding health conditions suggest the possibility that wider venules are a distinguishing feature of schizophrenia and not simply an artifact of co-occurring health problems in schizophrenia patients, as the widest venules were observed for the schizophrenia group. Moreover, wider venules were associated with a greater dimensional liability to experience psychosis symptoms in adulthood. This finding is consistent with theory and research suggesting that the same mechanisms underlie subthreshold symptoms and clinical disorder (24). Finally, wider venules were associated with childhood psychosis symptoms at age 11, which may suggest that pathological vascular mechanisms leading to the association between schizophrenia and wider venules operate from early life.

The specific pathophysiological mechanisms underlying wider retinal venular caliber are not entirely understood (2). Wider venules have been shown to be associated with inflammation (37–40), endothelial dysfunction (40, 41), and hypoxia/ischemia (12), for example. Notably, inflammation (42–44), endothelial dysfunction/dysregulation of the nitric oxide signaling pathway (45, 46), and hypoxia/ischemia (47) are all seen in schizophrenia. Genetic factors also influence retinal venular caliber (48–50). Interestingly, genetic linkage regions for venular caliber are implicated in endothelial function and vasculogenesis (48, 49). Thus, some individuals may have a genetic propensity to develop




FIGURE 2. Distribution of Retinal Venular Caliber for the Schizophrenia and Comparison Groups<sup>a</sup>

<sup>a</sup> Scores were adjusted for arteriolar caliber and sex and were standardized (mean=0.00, SD=1.00) on the population-representative cohort. The black vertical line represents the mean for the healthy group. Both parametric and nonparametric statistical analyses showed that individuals diagnosed with schizophrenia had significantly wider venules, a finding that does not depend on outliers.

wider venules. It is unclear whether venular caliber plays a causal role in the development of schizophrenia or whether it might represent an associated epiphenomenon. Nevertheless, it has been hypothesized that wider venules reflect, in part, cumulative structural damage to the

microvasculature (for example, from inflammation or endothelial dysfunction) and indicate problems with the oxygen supply to the brain (2, 12).

While our study is the first, to our knowledge, to investigate the microvasculature in living schizophrenia

**FIGURE 3. Standardized Mean Retinal Venular Caliber at age 38 as a Function of Childhood Psychosis Symptoms<sup>a</sup>**

<sup>a</sup> Venular caliber values were adjusted for arteriolar caliber and sex and were standardized on the population-representative cohort. As previously described (13), children with scores of 0, 1, and  $\geq 2$  were grouped as having no symptoms ( $N=673$ ; 50.2% were male), weak symptoms ( $N=103$ ; 66.0% male), or strong symptoms ( $N=13$ ; 61.5% male), respectively. At minimum, study members could enter the strong symptom group by obtaining a score of 1 (yes, likely) for two symptoms or by obtaining a score of 2 (yes, definitely) for one symptom. Children who exhibited strong psychosis symptoms had the widest venular calibers as adults. Error bars indicate standard error.

patients, our findings converge with a growing body of literature that implicates the vasculature in schizophrenia. First, individuals with schizophrenia are at increased risk of developing cardiovascular disease (25), and recent evidence suggests that the same genes influence both schizophrenia and risk for cardiovascular disease (51). Second, a large proportion of replicated candidate genes for schizophrenia are regulated by hypoxia or are expressed in the vasculature (47, 52). Third, altered cerebral blood flow and blood volume as well as mitochondrial dysfunction in schizophrenia have all been hypothesized to arise from vascular abnormalities (53–55). Fourth, individuals with schizophrenia show impaired vasodilation (56–58) and abnormalities of the nailfold capillary bed (59). Fifth, postmortem analysis of the brains of schizophrenia patients has revealed evidence of atypically simplified angioarchitecture and lack of normal arborization of vessels (60), ultrastructural capillary damage (61), and molecular alterations of the cerebral microvasculature (62). Overall, evidence of vascular involvement in schizophrenia is accumulating, and the long-standing hypothesis of vascular pathology in schizophrenia (see Figure S1 in the online data supplement) highlights the need for an innovative method to assess the microvasculature in living schizophrenia patients.

Results of our study should be interpreted in the context of limitations. First, the prevalence of schizophrenia in our cohort is high. Given the lack of clear boundaries between mental health and illness, it is possible that our cohort members diagnosed with schizophrenia would not be considered by all clinicians to have schizophrenia. However, over half of the members of our schizophrenia group had received treatment specifically for psychotic illness, and there were no differences in venular caliber between those who received treatment and those who did not. Second, our finding is based on a relatively small group of individuals who developed schizophrenia ( $N=27$ ). Larger samples are needed to determine the replicability and robustness of the finding. We note, however, two aspects of our study that bolster our findings and are important for psychiatric research aimed toward identifying biological abnormalities (63): 1) we reported effect sizes for diagnosed schizophrenia in relation to both healthy and medically or psychiatrically unhealthy comparison groups, a practice that can substantially reduce or eliminate biased and invalid conclusions (64); and 2) we showed an association between wider venules and latent dimensional liability to adult psychosis in the population-representative cohort. Doing this circumvented some of the problems associated with studying categorical diagnoses (63).

Another limitation is that we assessed retinal vessel caliber at a single time point (age 38), and thus we cannot know whether wider venules might be detectable before the onset of schizophrenia. Retinal imaging of microvessels is a relatively new technology that was not available in the early years of our longitudinal study. However, our finding of an association between psychosis symptoms at age 11, before the onset of schizophrenia, and venular caliber at age 38 suggests the hypothesis that abnormal vascular processes may begin in childhood. In support of this possibility, research indicates that variation in the retinal vessel calibers of children is informative, at least with regard to blood pressure (65, 66).

Retinal imaging makes possible the prospective tracking of vascular changes as they relate to the onset, waxing, and waning of symptoms, and research using longitudinal, high-risk, and experimental designs could use this method to address a variety of important questions. For example, longitudinal and high-risk studies can determine whether retinal vessel caliber in juveniles predicts risk of developing psychosis or accompanies the progression of schizophrenia, as might be expected given the neurodevelopmental nature of schizophrenia (67). Research questions could also be extended to examine associations between retinal vessel caliber and neuropsychological impairment in schizophrenia, as we previously showed that wider venular caliber in adulthood was associated with poorer neuropsychological test performance in childhood and midlife (31). Experimental studies are ideally suited to addressing whether changes in retinal

vessel caliber are associated with improvement or deterioration in symptoms. Along these lines, a recent study found that oxygen supplementation improved symptoms of schizophrenia, including neuropsychological functioning (68), and the addition of retinal imaging to this design could help elucidate the mechanisms by which treatment works.

Our results provide initial evidence of retinal vessel caliber abnormality (specifically wider venular caliber) in schizophrenia and psychosis, a finding that is consistent with the hypothesis of microvascular pathology in schizophrenia (69). The noninvasive nature of retinal imaging, its relative cost-effectiveness, and the availability of the technology in primary care, optometry, and ophthalmology centers all suggest the value of retinal imaging analysis as an exciting tool for schizophrenia research.

---

Received Feb. 19, 2013; revision received May 15, 2013; accepted June 3, 2013 (doi: 10.1176/appi.ajp.2013.13020234). From the Department of Psychology and Neuroscience; the Department of Psychiatry and Behavioral Sciences; the Institute for Genome Sciences and Policy; and the Duke Transdisciplinary Prevention Research Center, Center for Child and Family Policy, Duke University, Durham, N.C.; the Social, Genetic, and Developmental Psychiatry Centre and the Department of Psychosis Studies, Institute of Psychiatry, King's College London; the Department of Ophthalmology and the Singapore Eye Research Institute, Yong Loo Lin School of Medicine, National University of Singapore (NUS), Singapore; the Center for Quantitative Medicine, Duke-NUS Graduate Medical School, Singapore; the Center for Aging and the Study of Human Development, Duke University Medical Center, Durham; and the Dunedin Multidisciplinary Health and Development Research Unit, Department of Preventive and Social Medicine, School of Medicine, University of Otago, Dunedin, New Zealand. Address correspondence to Dr. Moffitt (terrie.moffitt@duke.edu).

Drs. Meier and Shalev contributed equally to this study.

Dr. Kapur has received grant support from AstraZeneca, Bristol-Myers Squibb, and GlaxoSmithKline and has served as a consultant, scientific adviser, or speaker for AstraZeneca, Bioline, Bristol-Myers Squibb, Eli Lilly, Janssen (Johnson & Johnson), Lundbeck, NeuroSearch, Otsuka, Pfizer, Roche, Servier, Solvay, and Wyeth. Dr. Keefe has received investigator-initiated research support from the Department of Veterans Affairs, Feinstein Institute for Medical Research, GlaxoSmithKline, NIMH, Novartis, Psychogenics, Research Foundation for Mental Hygiene, and the Singapore National Medical Research Council and has served as a speaker, consultant, or advisory board member for Abbott, Akebia, Amgen, Astellas, Asubio, BiolineRx, Biomarin, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly, EnVivo, Helicon, Lundbeck, Merck, Mitsubishi, Novartis, Otsuka, Pfizer, Roche, Shire, Sunovion, Takeda, and Targacept; he also receives royalties from the BACS testing battery and the MATRICS Battery (BACS Symbol Coding) and is a shareholder in NeuroCog Trials. The other authors report no financial relationships with commercial interests.

Supported by grant AG032282 from the National Institute on Aging and grant MR/K00381X from the U.K. Medical Research Council. The Dunedin Multidisciplinary Health and Development Research Unit is supported by the New Zealand Health Research Council. Dr. Meier was supported by grant P30 DA023026 from the National Institute on Drug Abuse. Dr. Shalev was supported by grant HD061298 from the National Institute of Child Health and Human Development and the Jacobs Foundation. Dr. Belsky was supported by grant T32AG000029 from the National Institute on Aging.

The authors thank the Dunedin Study members, their families, the Dunedin Multidisciplinary Health and Development Research Unit staff, and study founder Phil Silva.

## References

1. Meynert T: *Psychiatrie: Klinik der erkrankungen des vorderhirns*. Vienna, Braumüller, 1884
2. Sun C, Wang JJ, Mackey DA, Wong TY: Retinal vascular caliber: systemic, environmental, and genetic associations. *Surv Ophthalmol* 2009; 54:74–95
3. Patton N, Aslam T, Macgillivray T, Pattie A, Deary IJ, Dhillion B: Retinal vascular image analysis as a potential screening tool for cerebrovascular disease: a rationale based on homology between cerebral and retinal microvasculatures. *J Anat* 2005; 206: 319–348
4. Cheung CYL, Ikram MK, Sabanayagam C, Wong TY: Retinal microvasculature as a model to study the manifestations of hypertension. *Hypertension* 2012; 60:1094–1103
5. Ikram MK, Ong YT, Cheung CY, Wong TY: Retinal vascular caliber measurements: clinical significance, current knowledge, and future perspectives. *Ophthalmologica* 2013; 229:125–136
6. McGeechan K, Liew G, Macaskill P, Irwig L, Klein R, Klein BEK, Wang JJ, Mitchell P, Vingerling JR, de Jong PTVM, Witteman JCM, Breteler MMB, Shaw J, Zimmet P, Wong TY: Prediction of incident stroke events based on retinal vessel caliber: a systematic review and individual-participant meta-analysis. *Am J Epidemiol* 2009; 170:1323–1332
7. Ikram MK, de Jong FJ, Bos MJ, Vingerling JR, Hofman A, Koudstaal PJ, de Jong PTVM, Breteler MMB: Retinal vessel diameters and risk of stroke: the Rotterdam Study. *Neurology* 2006; 66: 1339–1343
8. Ikram MK, De Jong FJ, Van Dijk EJ, Prins ND, Hofman A, Breteler MMB, De Jong PTVM: Retinal vessel diameters and cerebral small vessel disease: the Rotterdam Scan Study. *Brain* 2006; 129:182–188
9. de Jong FJ, Schrijvers EMC, Ikram MK, Koudstaal PJ, de Jong PTVM, Hofman A, Vingerling JR, Breteler MMB: Retinal vascular caliber and risk of dementia: the Rotterdam Study. *Neurology* 2011; 76:816–821
10. Wong TY, Kamineni A, Klein R, Sharrett AR, Klein BE, Siscovick DS, Cushman M, Duncan BB: Quantitative retinal venular caliber and risk of cardiovascular disease in older persons: the Cardiovascular Health Study. *Arch Intern Med* 2006; 166: 2388–2394
11. Yatsuya H, Folsom AR, Wong TY, Klein R, Klein BEK, Sharrett AR; ARIC Study Investigators: Retinal microvascular abnormalities and risk of lacunar stroke: Atherosclerosis Risk in Communities Study. *Stroke* 2010; 41:1349–1355
12. de Jong FJ, Vernooij MW, Ikram MK, Ikram MA, Hofman A, Krestin GP, van der Lugt A, de Jong PTVM, Breteler MMB: Arterial oxygen saturation, cerebral blood flow, and retinal vessel diameters: the Rotterdam Study. *Ophthalmology* 2008; 115: 887–892
13. Poulton R, Caspi A, Moffitt TE, Cannon M, Murray R, Harrington H: Children's self-reported psychotic symptoms and adult schizophreniform disorder: a 15-year longitudinal study. *Arch Gen Psychiatry* 2000; 57:1053–1058
14. Cannon M, Caspi A, Moffitt TE, Harrington H, Taylor A, Murray RM, Poulton R: Evidence for early-childhood, pan-developmental impairment specific to schizophreniform disorder: results from a longitudinal birth cohort. *Arch Gen Psychiatry* 2002; 59:449–456
15. Reichenberg A, Caspi A, Harrington H, Houts R, Keefe RS, Murray RM, Poulton R, Moffitt TE: Static and dynamic cognitive deficits in childhood preceding adult schizophrenia: a 30-year study. *Am J Psychiatry* 2010; 167:160–169
16. Robins LN, Helzer JE, Croughan J, Ratcliff KS: National Institute of Mental Health Diagnostic Interview Schedule: its history, characteristics, and validity. *Arch Gen Psychiatry* 1981; 38: 381–389

17. Robins LN, Cottler L, Bucholz KK, Compton W: Diagnostic Interview Schedule for DSM-IV. St Louis, Mo, Washington University School of Medicine, 1995
18. Kendler KS, Gallagher TJ, Abelson JM, Kessler RC: Lifetime prevalence, demographic risk factors, and diagnostic validity of nonaffective psychosis as assessed in a US community sample: the National Comorbidity Survey. *Arch Gen Psychiatry* 1996; 53: 1022–1031
19. Dutta R, Murray RM, Allardyce J, Jones PB, Boydell JE: Mortality in first-contact psychosis patients in the UK: a cohort study. *Psychol Med* 2012; 42:1649–1661
20. Youssef HA, Kinsella A, Waddington JL: Evidence for geographical variations in the prevalence of schizophrenia in rural Ireland. *Arch Gen Psychiatry* 1991; 48:254–258
21. Arajärvi R, Suvisaari J, Suokas J, Schreck M, Haukka J, Hintikka J, Partonen T, Lönqvist J: Prevalence and diagnosis of schizophrenia based on register, case record, and interview data in an isolated Finnish birth cohort born 1940–1969. *Soc Psychiatry Psychiatr Epidemiol* 2005; 40:808–816
22. Torrey EF, McGuire M, O'Hare A, Walsh D, Spellman MP: Endemic psychosis in western Ireland. *Am J Psychiatry* 1984; 141: 966–970
23. Ferguson S, Blakely T, Allan B, Colling S: Suicide Rates in New Zealand: Exploring Associations With Social and Economic Factors. Wellington, New Zealand, Ministry of Health, 2005
24. van Os J, Linscott RJ, Myin-Germeys I, Delespaul P, Krabbendam L: A systematic review and meta-analysis of the psychosis continuum: evidence for a psychosis proneness-persistence-impairment model of psychotic disorder. *Psychol Med* 2009; 39:179–195
25. Hennekens CH, Hennekens AR, Hollar D, Casey DE: Schizophrenia and increased risks of cardiovascular disease. *Am Heart J* 2005; 150:1115–1121
26. Buckley PF, Miller BJ, Lehrer DS, Castle DJ: Psychiatric comorbidities and schizophrenia. *Schizophr Bull* 2009; 35: 383–402
27. Perloff D, Grim C, Flack J, Frohlich ED, Hill M, McDonald M, Morgenstern BZ: Human blood pressure determination by sphygmomanometry. *Circulation* 1993; 88:2460–2470
28. Cleeman JI, Grundy SM, Becker D, Clark LT, Cooper RS, Denke MA, Howard WJ, Hunnigake DB, Illingworth DR, Luepker RV, McBride P, McKenney JM, Pasternak RC, Stone NJ, Van Horn L, Brewer HB, Ernst ND, Gordon D, Levy D, Rifkind B, Rossouw JE, Savage P, Haffner SM, Orloff DG, Proschan MA, Schwartz JS, Sempos CT, Shero ST, Murray EZ; Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). *JAMA* 2001; 285:2486–2497
29. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care* 1997; 20:1183–1197
30. Costello A, Edelbrock C, Kalas R, Kessler M, Klaric SA: Diagnostic Interview Schedule for Children (DISC). Rockville, Md, National Institute of Mental Health, 1982
31. Shalev I, Moffitt TE, Wong TY, Meier MH, Houts RM, Ding J, Cheung CY, Ikram MK, Caspi A, Poulton R: Retinal vessel caliber and lifelong neuropsychological functioning: retinal imaging as an investigative tool for cognitive epidemiology. *Psychol Sci* 2013; 24:1198–1207
32. Cheung CYL, Hsu W, Lee ML, Wang JJ, Mitchell P, Lau QP, Hamzah H, Ho M, Wong TY: A new method to measure peripheral retinal vascular caliber over an extended area. *Microcirculation* 2010; 17:495–503
33. Knudtson MD, Lee KE, Hubbard LD, Wong TY, Klein R, Klein BEK: Revised formulas for summarizing retinal vessel diameters. *Curr Eye Res* 2003; 27:143–149
34. Liew G, Sharrett AR, Kronmal R, Klein R, Wong TY, Mitchell P, Kiffley A, Wang JJ: Measurement of retinal vascular caliber: issues and alternatives to using the arteriole to venule ratio. *Invest Ophthalmol Vis Sci* 2007; 48:52–57
35. Wong TY, Wang JJ, Rochtchina E, Klein R, Mitchell P: Does refractive error influence the association of blood pressure and retinal vessel diameters? The Blue Mountains Eye Study. *Am J Ophthalmol* 2004; 137:1050–1055
36. Cohen J: A power primer. *Psychol Bull* 1992; 112:155–159
37. Klein R, Klein BEK, Knudtson MD, Wong TY, Tsai MY: Are inflammatory factors related to retinal vessel caliber? The Beaver Dam Eye Study. *Arch Ophthalmol* 2006; 124:87–94
38. Ikram MK, de Jong FJ, Vingerling JR, Witteman JCM, Hofman A, Breteler MMB, de Jong PTVM: Are retinal arteriolar or venular diameters associated with markers for cardiovascular disorders? The Rotterdam Study. *Invest Ophthalmol Vis Sci* 2004; 45:2129–2134
39. Liew G, Sharrett AR, Wang JJ, Klein R, Klein BEK, Mitchell P, Wong TY: Relative importance of systemic determinants of retinal arteriolar and venular caliber: the Atherosclerosis Risk in Communities Study. *Arch Ophthalmol* 2008; 126:1404–1410
40. Wong TY, Islam FMA, Klein R, Klein BEK, Cotch MF, Castro C, Sharrett AR, Shahar E: Retinal vascular caliber, cardiovascular risk factors, and inflammation: the Multi-Ethnic Study of Atherosclerosis (MESA). *Invest Ophthalmol Vis Sci* 2006; 47: 2341–2350
41. Nguyen TT, Islam FMA, Farouque HMO, Klein R, Klein BEK, Cotch MF, Herrington DM, Wong TY: Retinal vascular caliber and brachial flow-mediated dilation: the Multi-Ethnic Study of Atherosclerosis. *Stroke* 2010; 41:1343–1348
42. Fan XD, Pristach C, Liu EY, Freudenreich O, Henderson DC, Goff DC: Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia. *Psychiatry Res* 2007; 149:267–271
43. Fan XD, Liu EY, Freudenreich O, Park JH, Liu DT, Wang JJ, Yi ZH, Goff D, Henderson DC: Higher white blood cell counts are associated with an increased risk for metabolic syndrome and more severe psychopathology in non-diabetic patients with schizophrenia. *Schizophr Res* 2010; 118:211–217
44. Potvin S, Stip E, Sepehry AA, Gendron A, Bah R, Kouassi E: Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. *Biol Psychiatry* 2008; 63:801–808
45. Israel AK, Seeck A, Boettger MK, Rachow T, Berger S, Voss A, Bär KJ: Peripheral endothelial dysfunction in patients suffering from acute schizophrenia: a potential marker for cardiovascular morbidity? *Schizophr Res* 2011; 128:44–50
46. Bernstein HG, Bogerts B, Keilhoff G: The many faces of nitric oxide in schizophrenia: a review. *Schizophr Res* 2005; 78:69–86
47. Schmidt-Kastner R, van Os J, W M Steinbusch H, Schmitz C: Gene regulation by hypoxia and the neurodevelopmental origin of schizophrenia. *Schizophr Res* 2006; 84:253–271
48. Xing C, Klein BEK, Klein R, Jun G, Lee KE, Iyengar SK: Genome-wide linkage study of retinal vessel diameters in the Beaver Dam Eye Study. *Hypertension* 2006; 47:797–802
49. Ikram MK, Sim X, Jensen RA, Cotch MF, Hewitt AW, Ikram MA, Wang JJ, Klein R, Klein BEK, Breteler MMB, Cheung N, Liew G, Mitchell P, Uitterlinden AG, Rivadeneira F, Hofman A, de Jong PTVM, van Duijn CM, Kao L, Cheng CY, Smith AV, Glazer NL, Lumley T, McKnight B, Psaty BM, Jonasson F, Eiriksdottir G, Aspelund T, Harris TB, Launer LJ, Taylor KD, Li XH, Iyengar SK, Xi QS, Sivakumaran TA, Mackey DA, Macgregor S, Martin NG, Young TL, Bis JC, Wiggins KL, Heckbert SR, Hammond CJ, Andrew T, Fahy S, Attia J, Holliday EG, Scott RJ, Islam FMA, Rotter JJ, McAuley AK, Boerwinkle E, Tai ES, Gudnason V, Siscovick DS,



- Vingerling JR, Wong TY, Consortium GB; Global BPgen Consortium: Four novel loci (19q13, 6q24, 12q24, and 5q14) influence the microcirculation in vivo. *PLoS Genet* 2010; 6:e1001184
50. Fahy SJ, Sun C, Zhu G, Healey PR, Spector TD, Martin NG, Mitchell P, Wong TY, Mackey DA, Hammond CJ, Andrew T: The relationship between retinal arteriolar and venular calibers is genetically mediated, and each is associated with risk of cardiovascular disease. *Invest Ophthalmol Vis Sci* 2011; 52: 975–981
  51. Andreassen OA, Djurovic S, Thompson WK, Schork AJ, Kendler KS, O'Donovan MC, Rujescu D, Werge T, van de Bunt M, Morris AP, McCarthy MI, Roddey JC, McEvoy LK, Desikan RS, Dale AM; International Consortium for Blood Pressure GWAS; Diabetes Genetics Replication and Meta-analysis Consortium; Psychiatric Genomics Consortium Schizophrenia Working Group: Improved detection of common variants associated with schizophrenia by leveraging pleiotropy with cardiovascular-disease risk factors. *Am J Hum Genet* 2013; 92:197–209
  52. Schmidt-Kastner R, van Os J, Esquivel G, Steinbusch HW, Rutten BP: An environmental analysis of genes associated with schizophrenia: hypoxia and vascular factors as interacting elements in the neurodevelopmental model. *Mol Psychiatry* 2012; 17:1194–1205
  53. Bachneff SA: Regional cerebral blood flow in schizophrenia and the local circuit neurons hypothesis. *Schizophr Bull* 1996; 22: 163–182
  54. Cohen BM, Yurgelun-Todd D, English CD, Renshaw PF: Abnormalities of regional distribution of cerebral vasculature in schizophrenia detected by dynamic susceptibility contrast MRI. *Am J Psychiatry* 1995; 152:1801–1803
  55. Prabakaran S, Swatton JE, Ryan MM, Huffaker SJ, Huang J TJ, Griffin JL, Wayland M, Freeman T, Dudbridge F, Lilley KS, Karp NA, Hester S, Tkachev D, Mimmack ML, Yolken RH, Webster MJ, Torrey EF, Bahn S: Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. *Mol Psychiatry* 2004; 9:684–697, 643
  56. Ward PE, Sutherland J, Glen EMT, Glen AIM: Niacin skin flush in schizophrenia: a preliminary report. *Schizophr Res* 1998; 29: 269–274
  57. Lien YJ, Huang SS, Liu CM, Hwu HG, Faraone SV, Tsuang MT, Chen WJ: A genome-wide quantitative linkage scan of niacin skin flush response in families with schizophrenia. *Schizophr Bull* 2013; 39:68–76
  58. Hudson CJ, Lin A, Cogan S, Cashman F, Warsh JJ: The niacin challenge test: clinical manifestation of altered transmembrane signal transduction in schizophrenia? *Biol Psychiatry* 1997; 41: 507–513
  59. Curtis CE, Iacono WG, Beiser M: Relationship between nailfold plexus visibility and clinical, neuropsychological, and brain structural measures in schizophrenia. *Biol Psychiatry* 1999; 46: 102–109
  60. Senitz D, Winkelmann E: [Neuronal structure abnormality in the orbito-frontal cortex of schizophrenics.] *J Hirnforsch* 1991; 32: 149–158 (German)
  61. Uranova NA, Zimina IS, Vikhrev A OV, Krukov NO, Rachmanova VI, Orlovskaya DD: Ultrastructural damage of capillaries in the neocortex in schizophrenia. *World J Biol Psychiatry* 2010; 11: 567–578
  62. Harris LW, Wayland M, Lan M, Ryan M, Giger T, Lockstone H, Wuethrich I, Mimmack M, Wang L, Kotter M, Craddock R, Bahn S: The cerebral microvasculature in schizophrenia: a laser capture microdissection study. *PLoS ONE* 2008; 3:e3964
  63. Kapur S, Phillips AG, Insel TR: Why has it taken so long for biological psychiatry to develop clinical tests and what to do about it? *Mol Psychiatry* 2012 17:1174–1179
  64. Schwartz S, Susser E: The use of well controls: an unhealthy practice in psychiatric research. *Psychol Med* 2011; 41: 1127–1131
  65. Li LJ, Cheung CYL, Liu Y, Chia A, Selvaraj P, Lin XY, Chan YM, Varma R, Mitchell P, Wong TY, Saw SM: Influence of blood pressure on retinal vascular caliber in young children. *Ophthalmology* 2011; 118:1459–1465
  66. Gopinath B, Baur LA, Wang JJ, Teber E, Liew G, Cheung N, Wong TY, Mitchell P: Blood pressure is associated with retinal vessel signs in preadolescent children. *J Hypertens* 2010; 28:1406–1412
  67. Insel TR: Rethinking schizophrenia. *Nature* 2010; 468:187–193
  68. Bloch Y, Applebaum J, Osher Y, Amar S, Azab AN, Agam G, Belmaker RH, Bersudsky Y: Normobaric hyperoxia treatment of schizophrenia. *J Clin Psychopharmacol* 2012; 32:525–530
  69. Hanson DR, Gottesman II: Theories of schizophrenia: a genetic-inflammatory-vascular synthesis. *BMC Med Genet* 2005; 6:7